RE:RE:Moody's Announces Credit NegativeYour number looks a lot closer to the mark Roller. If Lettuce had bothered to look before lying, she and Cahoades would have seen that Ani pharma indicated TOTAL 12 month trailing sales for the drug was ONLY $23 million. That is total US sales in thier release and estimated by IMS health. I assume ROW are not touched.
Roller007 wrote: I posted that last week, it's not 25-50 million and they didn't lose their Moody's rating. But nice try Yolanda. The fact of the matter is that if a company went to the expense of FDA approval and regulatory process to introduce a generic of nilandron then that shows the market for this drug is growing and can handle two formulations. Sometimes competition has a healthy impact on a drug if the market demand is growing. Nilandron is about 2.7% of Cxr revenue, assuming they lose half that, which is beyond worst case scenario, they lose 1.4% of total revenue which accounts for about 15 million. Anyone can read the Moody's article and judge for themselfs. And I think this will give Cxr a chance to raise the price of nilandron which will make up for any lost revenue.